版本:
中国

BRIEF-Alnylam Pharma says discontinues revusiran development

Oct 5 Alnylam Pharmaceuticals Inc

* Alnylam pharmaceuticals discontinues revusiran development

* Decision to discontinue development of revusiran does not affect patisiran

* Decision to discontinue development of revusiran does not affect any other investigational rnai therapeutic program in development

* Upon recommendation of endeavour phase 3 study dmc to suspend dosing, decided to discontinue development of revusiran

* Alnylam pharmaceuticals inc says decision does not impact patisiran or any other rnai therapeutic program in development

* Subsequently reviewed unblinded endeavour data which revealed an imbalance of mortality in revusiran arm as compared to placebo

* Reaffirms its "alnylam 2020" guidance and remains committed to advancement of investigational rnai therapeutics Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐